The purpose of this study is to 1) see whether chemotherapy with PSC833 and doxorubicin (ADR) is effective in treating patients with breast cancer; 2) evaluate side effects; 3) study how p-glycoprotein interacts with PSC833 and ADR; and 4) determine how the body process both drugs. Protocol activity has been slower than anticipated. There is no preliminary data to report at this time.
Showing the most recent 10 out of 1267 publications